A Cuban medication to treat chronic hepatitis B, HeberNasvac, created by scientists at the Genetic Engineering and Biotechnology Center (CIGB), is currently undergoing clinical trials in collaboration with the French company Abivax
A Cuban medication to treat chronic hepatitis B, HeberNasvac, created
by scientists at the Genetic Engineering and Biotechnology Center
(CIGB), is currently undergoing clinical trials in collaboration with
the French company Abivax.
The product has been undergoing safety and efficacy tests for several years, stated a CIGB specialist.
According to Iris Lugo Carro, the clinical trials being carried out
by Cuban scientists and Abivax - involving 230 patients from eight Asian
countries, and the participation of 50 clinical centers - are being
realized under regulation ABX 203.
To date, the study has been approved by the regulatory authorities of
Australia, New Zealand, Singapore, South Korea, Taiwan, Hong Kong, the
Philippines and Thailand.
Read more...Labels: ABIVAX ABX203, clinical trials, Cuba, HeberNasvac